Solventum Corp. (SOLV)
NYSE · Healthcare · Medical Instruments & Supplies
Solventum Corp. is a Healthcare company with a market capitalization of $14.34B and a trailing P/E ratio of 10.3.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 5, 2026 | $1.48 | $1.35 | +9.6% |
| Q4 2025 | February 26, 2026 | $1.57 | $1.50 | +4.7% |
| Q3 2025 | November 6, 2025 | $1.50 | $1.43 | +4.9% |
| Q2 2025 | August 7, 2025 | $1.69 | $1.45 | +16.6% |
| Q1 2025 | May 8, 2025 | $1.34 | $1.22 | +9.8% |
| Q4 2024 | February 27, 2025 | $1.41 | $1.50 | -6.0% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 4,297,389 | 2.45% | 4.5 | -14.4% |
| June 30, 2026 | 5,023,381 | 2.86% | 3.1 | -7.8% |
| June 15, 2026 | 5,445,902 | 3.10% | 3.0 | -28.2% |
| May 29, 2026 | 7,582,360 | 4.32% | 2.7 | -3.9% |
| May 15, 2026 | 7,893,674 | 4.50% | 4.1 | +21.7% |
| April 30, 2026 | 6,484,631 | 3.70% | 6.4 | +1.6% |
| April 15, 2026 | 6,383,578 | 3.64% | 5.0 | +18.6% |
| March 31, 2026 | 5,383,477 | 3.07% | 3.5 | +35.7% |
Other Medical Instruments & Supplies Stocks
Frequently Asked Questions
What is Solventum Corp.'s market cap?
As of August 13, 2026, Solventum Corp. (SOLV) has a market capitalization of $14.34B.
What is Solventum Corp.'s P/E ratio?
Solventum Corp. trades at a trailing price-to-earnings (P/E) ratio of 10.3. Its forward P/E is 12.9.
Does Solventum Corp. pay a dividend?
Solventum Corp. does not currently pay a dividend.
What sector is SOLV in?
Solventum Corp. is in the Healthcare sector, specifically the Medical Instruments & Supplies industry.
What is Solventum Corp.'s short interest?
As of the July 15, 2026 FINRA settlement, 4,297,389 SOLV shares were sold short, or 2.45% of shares outstanding. Days to cover: 4.5. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Solventum Corp.'s revenue?
In its latest reported fiscal year (ending December 31, 2025), Solventum Corp. reported revenue of $8.32B and net income of $1.56B.
Ask your own questions about SOLV
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.